Serge Fratté

883 total citations
24 papers, 378 citations indexed

About

Serge Fratté is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Serge Fratté has authored 24 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Surgery and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Serge Fratté's work include Colorectal Cancer Treatments and Studies (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Serge Fratté is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Serge Fratté collaborates with scholars based in France, Italy and Austria. Serge Fratté's co-authors include Jean‐Louis Gendrault, André Kirn, Anne‐Marie Steffan, Julien Taı̈eb, Déwi Vernerey, M. Messner, Sylvie Naveau, Thierry Poynard, Jean‐Philippe Miguet and B Launois and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Serge Fratté

22 papers receiving 366 citations

Peers

Serge Fratté
Javier Fernández‐Seara Spain
Dai Manaka Japan
Masami Yamauchi Japan
S. Kubicka Germany
Fa‐Zu Qiu China
Wusheng Lu China
Hyun Yang South Korea
Angel Alsina United States
J Belghiti France
Chunping Su China
Javier Fernández‐Seara Spain
Serge Fratté
Citations per year, relative to Serge Fratté Serge Fratté (= 1×) peers Javier Fernández‐Seara

Countries citing papers authored by Serge Fratté

Since Specialization
Citations

This map shows the geographic impact of Serge Fratté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Fratté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Fratté more than expected).

Fields of papers citing papers by Serge Fratté

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Fratté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Fratté. The network helps show where Serge Fratté may publish in the future.

Co-authorship network of co-authors of Serge Fratté

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Fratté. A scholar is included among the top collaborators of Serge Fratté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Fratté. Serge Fratté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Basile, Debora, Chloé Broudin, Jean-François Emile, et al.. (2022). Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Annals of Oncology. 33(6). 628–637. 27 indexed citations
3.
Henriques, Julie, Déwi Vernerey, Hamadi Almotlak, et al.. (2022). Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. Frontiers in Oncology. 12. 763926–763926. 1 indexed citations
4.
Delattre, Jean-François, Romain Cohen, Julie Henriques, et al.. (2020). Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Journal of Clinical Oncology. 38(15). 1702–1710. 55 indexed citations
5.
Cohen, Romain, Julie Henriques, Jean‐François Emile, et al.. (2019). Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. Journal of Clinical Oncology. 37(15_suppl). 3519–3519. 3 indexed citations
6.
Taı̈eb, Julien, Franck Bonnetain, Laurent Mineur, et al.. (2017). Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. Annals of Oncology. 28. v158–v158. 9 indexed citations
7.
Taı̈eb, Julien, Karine Le Malicot, Josep Tabernero, et al.. (2016). Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. Annals of Oncology. 27. vi152–vi152. 2 indexed citations
8.
Taı̈eb, Julien, Karine Le Malicot, Josep Tabernero, et al.. (2016). Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients. Annals of Oncology. 28(4). 824–830. 40 indexed citations
9.
Kim, Stéfano, Sophie Paget‐Bailly, Mathieu Messager, et al.. (2016). Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. European Journal of Surgical Oncology. 43(1). 218–225. 11 indexed citations
10.
Jary, Marine, Déwi Vernerey, Thierry Lecomte, et al.. (2015). Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 24(3). 603–612. 16 indexed citations
11.
Jary, Marine, François Ghiringhelli, Marion Jacquin, et al.. (2014). Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemotherapy and Pharmacology. 74(1). 141–150. 6 indexed citations
12.
Fiteni, Frédéric, Marine Jary, Franck Monnien, et al.. (2014). Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterology. 14(1). 143–143. 19 indexed citations
13.
14.
Fratté, Serge, et al.. (2008). Évaluation de la qualité des soins en endoscopie digestive : étude de 202 coloscopies totales consécutives. La Presse Médicale. 37(9). 1212–1219. 1 indexed citations
15.
Doffoël, M, D Vetter, Olivier Bouché, et al.. (2005). Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. Journal of Clinical Oncology. 23(16_suppl). 4006–4006. 5 indexed citations
16.
Queneau, P, Jean-Pierre Bronowicki, Gérard Thiéfin, et al.. (2001). Treatment of mild chronic hepatitis C with interferon α-2b: results of a multi-centre randomized study in 80 patients. European Journal of Gastroenterology & Hepatology. 13(2). 143–147. 3 indexed citations
17.
Poynard, Thierry, Philippe Barthélémy, Serge Fratté, et al.. (1994). Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. The Lancet. 344(8921). 502–507. 70 indexed citations
18.
Doffoël, M, et al.. (1993). [Liver transplantation in alcoholic cirrhosis].. PubMed. 43(9). 1124–8. 1 indexed citations
19.
Fratté, Serge, Jean‐Louis Gendrault, Anne‐Marie Steffan, & André Kirn. (1991). Comparative ultrastructural study of rat livers preserved in euro-collins or university of wisconsin solution. Hepatology. 13(6). 1173–1180. 49 indexed citations
20.
Fratté, Serge. (1991). Comparative ultrastructural study of rat livers preserved in euro-collins or university of wisconsin solution. Hepatology. 13(6). 1173–1180. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Fernández‐Seara Breakdown of academic impact, for papers by Dai Manaka Breakdown of academic impact, for papers by Masami Yamauchi Breakdown of academic impact, for papers by S. Kubicka Breakdown of academic impact, for papers by Fa‐Zu Qiu Breakdown of academic impact, for papers by Wusheng Lu Breakdown of academic impact, for papers by Hyun Yang Breakdown of academic impact, for papers by Angel Alsina Breakdown of academic impact, for papers by J Belghiti Breakdown of academic impact, for papers by Chunping Su
Rankless by CCL
2026